ReNeuron Group PLC - ESG Rating & Company Profile powered by AI
This assessment of ReNeuron Group PLC leverages data points from across the web as well as from public filings by ReNeuron Group PLC. This webpage is a free ESG analysis covering ReNeuron Group PLC. Other corporations in the rating peer group for ReNeuron Group PLC are displayed.
ReNeuron Group PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.6; made up of an environmental score of 5.3, social score of 6.4 and governance score of 8.0.
6.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 337 | Sonoma Pharmaceuticals Inc | 6.7 | High |
| 337 | Zhong Yuan Bio-Technology Holdings Ltd | 6.7 | High |
| 389 | ReNeuron Group PLC | 6.6 | High |
| 389 | Austar Lifesciences Ltd | 6.6 | High |
| 389 | Alligator Bioscience AB | 6.6 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does ReNeuron Group PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes ReNeuron Group PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes ReNeuron Group PLC report the average age of the workforce?
Sign up for free to unlockDoes ReNeuron Group PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes ReNeuron Group PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes ReNeuron Group PLC disclose cybersecurity risks?
Sign up for free to unlockDoes ReNeuron Group PLC offer flexible work?
Sign up for free to unlockDoes ReNeuron Group PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes ReNeuron Group PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes ReNeuron Group PLC conduct supply chain audits?
Sign up for free to unlockDoes ReNeuron Group PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes ReNeuron Group PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes ReNeuron Group PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes ReNeuron Group PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes ReNeuron Group PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes ReNeuron Group PLC disclose water use targets?
Sign up for free to unlockDoes ReNeuron Group PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid ReNeuron Group PLC have a product recall in the last two years?
Sign up for free to unlockDoes ReNeuron Group PLC disclose incidents of discrimination?
Sign up for free to unlockDoes ReNeuron Group PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas ReNeuron Group PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes ReNeuron Group PLC disclose parental leave metrics?
Sign up for free to unlockDoes ReNeuron Group PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes ReNeuron Group PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes ReNeuron Group PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes ReNeuron Group PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes ReNeuron Group PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes ReNeuron Group PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs ReNeuron Group PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes ReNeuron Group PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes ReNeuron Group PLC disclose its waste policy?
Sign up for free to unlockDoes ReNeuron Group PLC report according to TCFD requirements?
Sign up for free to unlockDoes ReNeuron Group PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes ReNeuron Group PLC disclose energy use targets?
Sign up for free to unlockDoes ReNeuron Group PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes ReNeuron Group PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for ReNeuron Group PLC
These potential risks are based on the size, segment and geographies of the company.
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.